Choose a language and wait for the translated text.
Shots:
Lupin, through its wholly owned subsidiary VISUfarma B.V., entered into an exclusive licensing agreement with Visus Therapeutics, a wholly owned subsidiary of Tenpoint Therapeutics, to commercialize YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% for presbyopia in the European Union, United Kingdom, Switzerland, Norway, and Iceland
Under the agreement, VISUfarma will hold exclusive rights for regulatory activities, commercialization, marketing, promotion, distribution, and sale of YUVEZZI in the licensed territories
VISUfarma will make a strategic investment in Visus. Tenpoint and Visus, individually or collectively,ย will also be eligible for regulatory and commercial milestones and tiered royalties based on net sales
Ref:ย Lupin | Image:ย Lupin & Tenpoint| Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
The post Lupin and Tenpoint Therapeutics Partner to Commercialize YUVEZZI in Key European Markets for Presbyopia appeared first on PharmaShots.
